The HIV community is closely following the latest news about FDA clinical trials of PRO 140. Early results indicate that infected patients could lead normal lives with possibly one dose a month.
"The worldwide AIDS community could stop gulping down as many as 30 toxic pills a week to control their viral load. If our FDA trials continue to have such dramatic success, we can possibly offer those infected with HIV an opportunity to finally lead some type of normal life without a daily pill regime," said Nader Pourhassan, CEO, CytoDyn Inc., clinical developer of PRO 140. "This could be the first self-injectable HIV antibody on the global market. A once-a-week dose of two PRO 140 shots, one in each thigh, or possibly a once-a-month dose, can control their viral loads enough to lead a fairly normal life,"
As documented in the Phase2b clinical trial, PRO 140 successfully kept viral loads suppressed for one month in 98 percent of HIV patients tested. And some HIV patients using PRO 140 are continuing to experience a completely suppressed viral load for the last 11 months. With positive results in the upcoming Phase 3 studies, PRO 140 could be commercial in 2017. Full story here!
No comments:
Post a Comment